Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

icine, Hematology/Neurology, and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and reported revenues in 2007 of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States. Genzyme(R), Campath(R) and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Daktari Diagnostics today announced a ... United States and Canada , ... The deal, worth up to $8.5 million over the next ... clinical validation and regulatory approval of Daktari,s HCV test. ... point-of-care instrument that can detect low levels of virus directly ...
(Date:8/31/2015)... Aug. 31, 2015  On August 5, 2015, the ... Oregon denied motions to dismiss securities class ... ) and certain of its directors. The class actions ... and dump" scheme to artificially inflate Galena,s stock price, ... stock price was inflated, sold massive amounts of their ...
(Date:8/31/2015)... -- Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: ... of delivering its patented (US Patent 8,263,571) gene ... a clinically approved formulation as delivery system.  The ... silencing therapeutics in which the gene silencing drug ... By utilizing a local delivery system, potential toxicities ...
Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... FREDERICKSBURG, Va., Feb. 17, 2011 Radiologic Associates ... Gently Campaign to increase awareness of opportunities to lower ... initiative of the Alliance for Radiation Safety in Pediatric ... undergone additional training in ways to reduce radiation exposure, ...
... Feb. 17, 2011 The method represented in the ... respiratory arterial pressure wave (a blood wave that ... blood pressure readings to provide healthcare professionals and users ... on systemic blood pressure. (Logo: ...
Cached Medicine Technology:Radiologic Associates of Fredericksburg Announces Image Gently Campaign to 'Child Size' Doses for Children 2ICAP Ocean Tomo Announces Advanced Techniques for Measuring Blood Pressure From Coherence L.L.C. 2
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical and ... orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , Dr. ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... digital marketing communications company announced today that it has officially launched a new ... the new website and brand refresh are more closely aligned with the company’s ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo is pleased to announce ... Sauna. After months of extensive engineering and design of our newest sauna model, the ... elements and is offered at a very attractive price-point. , Before outdoor saunas ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement (CDI) and medical ... a patent pending ICD-10 solution - ezCAC is an enterprise-level coding solution that ...
(Date:8/31/2015)... Valley, CA (PRWEB) , ... August 31, 2015 , ... ... Ghasri, to the practice. Dr. Pedram Ghasri is a graduate of the University of ... neuroscience and continued his studies at the University of California, Irvine Medical School. As ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2
... of outdated inspection practices desperately needed, critics say ... system that guarantees the safety of food in the ... new report finds. , Gaps in the food safety ... inconsistencies among agencies protecting food safety, according to the ...
... have a significantly higher risk of developing Alzheimers ... remains unexplained. Now, researchers at the Salk Institute ... for the diabetes Alzheimers interaction. , In ... of Neurobiology of Aging, investigators led by David ...
... becoming three kinds of cardiac cells , , WEDNESDAY, April ... created from mouse skin cells reprogrammed to have the ... researchers at the University of California, Los Angeles. ... induced pluripotent stem (iPS) cells, which don,t involve the ...
... Actually Work in Real ... ... healthcare community, announced the launch of an,innovative new tool that brings patient ... drugs, and eight out of,ten surfing the web for their healthcare information, ...
... lifestyles, WASHINGTON, April 29 Blue Cross ... of all sizes to get,their workers to take ... inactive lifestyles and preventable health conditions,have on the ... companies,are holding lunchtime walks across America as part ...
... Inc.,(NYSE: HI ) today announced that its Board ... traded company of $0.1825 per share,on the company,s common ... of record at the close of business on June ... approve this inaugural dividend is based,on the strength of ...
Cached Medicine News:Health News:Report Slams U.S. Food Safety System 2Health News:Report Slams U.S. Food Safety System 3Health News:Report Slams U.S. Food Safety System 4Health News:Salk study links diabetes and Alzheimer's disease 2Health News:Salk study links diabetes and Alzheimer's disease 3Health News:Mouse Skin Cells Reprogrammed to Act Like Embryonic Stem Cells 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 3Health News:Blue Cross and Blue Shield Companies to Get Workers Out of The Office and on Their Feet in All 50 States 2Health News:Blue Cross and Blue Shield Companies to Get Workers Out of The Office and on Their Feet in All 50 States 3Health News:Blue Cross and Blue Shield Companies to Get Workers Out of The Office and on Their Feet in All 50 States 4Health News:Blue Cross and Blue Shield Companies to Get Workers Out of The Office and on Their Feet in All 50 States 5Health News:Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company 2
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
... B3 Triplanar hip joint is ... - extension, abduction - Ad-duction, ... our Boston Post-Op Hip Orthosis. ... custom Hip Spicas in both ...
... advance in walker design in years. A real step ... bearing surfaces of the foot rest on adaptive areas ... heel strike. The footbed in the sole conforms to ... and stability. , ,No leg length discrepancy; Heel ...
... The High Tide walker provides comfortable stability ... of the lower leg, stress fractures of ... fractures of the ankle. Extension pads for ... patients.The shorter Low Tide walker with midcalf ...
Medicine Products: